Zenas Biopharma
Zenas and InnoCare Sign $2B+ Global License Deal for Orelabrutinib
Zenas BioPharma and InnoCare Pharma announce a $2 billion-plus global license agreement covering orelabrutinib (BTK inhibitor) for multiple sclerosis and two additional autoimmune programs, expanding Zenas’s neuroimmunology pipeline.